Asset Details
Do you wish to reserve the book?
Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures
Do you wish to request the book?
Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures
2022
Overview
Triple negative breast cancer (TNBC) metastases are assumed to exhibit similar functions in different organs as in the original primary tumor. However, studies of metastasis are often limited to a comparison of metastatic tumors with primary tumors of their origin, and little is known about the adaptation to the local environment of the metastatic sites. We therefore used transcriptomic data and metabolic network analyses to investigate whether metastatic tumors adapt their metabolism to the metastatic site and found that metastatic tumors adopt a metabolic signature with some similarity to primary tumors of their destinations. The extent of adaptation, however, varies across different organs, and metastatic tumors retain metabolic signatures associated with TNBC. Our findings suggest that a combination of anti-metastatic approaches and metabolic inhibitors selected specifically for different metastatic sites, rather than solely targeting TNBC primary tumors, may constitute a more effective treatment approach.
Publisher
National Academy of Sciences
Subject
/ Biophysics and Computational Biology
/ genome-scale metabolic models
/ Humans
/ Metabolic Networks and Pathways - genetics
/ Neoplasm Metastasis - drug therapy
/ Neoplasm Metastasis - genetics
/ Neoplasm Metastasis - pathology
/ Organs
/ triple negative breast cancer
/ Triple Negative Breast Neoplasms - drug therapy
/ Triple Negative Breast Neoplasms - genetics
/ Triple Negative Breast Neoplasms - metabolism
/ Triple Negative Breast Neoplasms - pathology
/ Tumors
